Based on Zhang Yidong (εΌ εΏδΈ), Investing in Core Assets (ζθ΅ζ ΈεΏθ΅δΊ§) (2020)
Zhang Yidong's central thesis is that global capital markets are undergoing a secular structural shift: returns increasingly concentrate in a narrow set of high-quality companies he calls "core assets" (ζ ΈεΏθ΅δΊ§). This is not a temporary style rotation but a permanent reordering driven by three irreversible forces:
Economic maturation. As GDP growth decelerates, the era of broad-based rising tides is over. Only companies with genuine competitive advantages continue to compound value. The tail of mediocre companies stagnates or declines.
Institutionalization of capital. Retail-dominated speculation gives way to institutional ownership. Mutual funds, insurance capital, pension funds, and foreign investors all gravitate toward quality, liquidity, and transparency β the defining attributes of core assets.
Globalization of valuation. With Stock Connect, MSCI inclusion, and FTSE Russell integration, A-share core assets are priced against global peers. Chinese consumer leaders trade in the same valuation universe as Nestle, LVMH, and Procter & Gamble. Mispricing narrows; quality commands a premium.
The practical implication for investors: abandon the old playbook of chasing small-cap momentum and thematic speculation. Instead, build concentrated portfolios of best-in-class companies, buy them at reasonable valuations, and hold through full market cycles. The compounding effect of owning businesses with durable 15-25% ROE over 5-10 years overwhelms any short-term trading edge.
Zhang argues that China's A-share market circa 2020 sits at an inflection point comparable to the United States in the early 1980s, Japan in the late 1970s, and South Korea in the early 2000s β each of which saw a dramatic and permanent re-rating of quality blue chips relative to the broader market.
A core asset is a company that satisfies ALL of the following criteria simultaneously:
| Dimension | Requirement |
|---|---|
| Competitive Moat | Durable structural advantage (brand, scale, network, patents) |
| Industry Leadership | #1 or #2 market share in its primary segment |
| Cash Flow Quality | Positive and growing free cash flow over trailing 3-5 years |
| Return on Equity | ROE consistently above 15%, ideally above 20% |
| Brand / Pricing Power | Ability to raise prices without losing volume |
| Management Quality | Proven, aligned management with long tenure and skin in game |
| Governance | Transparent reporting, minority shareholder protections |
Primary filters (all must pass):
ROE (trailing 3-year average) >= 15%
Gross margin (trailing 3-year average) >= 30% (sector-adjusted)
Revenue CAGR (trailing 5 years) >= 10%
Free cash flow > 0 in at least 4 of last 5 years
Market share Top 2 in primary segment
Debt-to-equity < 1.0 (ex-financials)
Dividend payout or buyback history Consistent capital return program
Secondary filters (scoring model, not hard cutoff):
+3 points: ROE > 20%
+2 points: Revenue CAGR > 15%
+2 points: Net margin expanding over 3 years
+2 points: FCF/Net Income > 80% (high earnings quality)
+1 point: Insider buying in trailing 12 months
+1 point: Northbound (foreign) ownership increasing
+1 point: Analyst coverage by 10+ brokerages
-2 points: Revenue concentration > 50% from single client
-2 points: Related-party transactions > 10% of revenue
-3 points: Auditor qualification or restatement in 3 years
Minimum qualifying score: 5 points after secondary filters.
Zhang identifies four primary sectors where core assets cluster:
Consumer Staples (30-35% weight): Baijiu (liquor), dairy, condiments, household goods. These businesses have the strongest brand moats, highest pricing power, and most predictable cash flows. Kweichow Moutai is the archetype.
Healthcare (20-25% weight): Innovative pharma, CRO/CDMO platforms, medical devices, leading hospitals/clinics. Driven by aging demographics and healthcare spending growth at 2-3x GDP growth rate.
Technology (20-25% weight): Platform internet companies, semiconductor leaders, cloud infrastructure, consumer electronics supply chain champions. Requires more nuanced analysis due to faster disruption cycles.
Financials (15-20% weight): Leading insurance companies, top-tier joint-stock banks, wealth management platforms. The best financials in China trade at deep discounts to book value despite ROE superiority.
The outperformance is not merely about valuation re-rating. It comes from three compounding mechanisms:
Earnings compounding: A 20% ROE business doubles equity every 3.8 years. Over a 10-year period, even with zero multiple expansion, the stock price roughly tracks this compounding path.
Market share consolidation: In a maturing economy, industry leaders gain share from weaker competitors. Supply-side reform, environmental regulation, and rising compliance costs all favor scale players. Core assets grow faster than their industries.
Valuation re-rating: As institutional and foreign ownership rises, the "quality premium" in valuation multiples structurally increases. A stock trading at 15x earnings may re-rate to 25x as its shareholder base shifts from retail to institutional. This is a one-time but powerful tailwind.
Zhang frames China's economic evolution in three phases:
| Phase | Period | Growth Driver | Market Character |
|---|---|---|---|
| I | 2001-2010 | Investment & exports | Cyclicals, commodities lead |
| II | 2011-2020 | Transition period | Small-cap speculation persists |
| III | 2020+ | Consumption & innovation | Core assets dominate |
In Phase III, GDP growth settles into the 4-6% range. Aggregate growth slows, but the composition shifts dramatically: consumption rises from ~55% to 65-70% of GDP, services overtake manufacturing, and innovation spending accelerates. Companies aligned with this structural shift capture a disproportionate share of incremental economic value.
Lower structural interest rates favor core assets through two channels:
Discount rate effect: Lower risk-free rates mechanically increase the present value of future cash flows. Since core assets have longer duration (more value in distant cash flows), they benefit disproportionately from rate declines.
Yield scarcity: As bond yields fall below 3%, institutional investors are forced up the risk curve. Core assets with 2-3% dividend yields plus 10-15% earnings growth become compelling substitutes for fixed income. Insurance companies and pension funds, in particular, become natural buyers.
Zhang emphasizes that China's 10-year government bond yield declining from 4%+ to the 2.5-3.5% range is a secular shift, not cyclical. This structurally supports higher equity valuations for quality companies.
The opening of China's capital account is the single most important structural driver for core asset re-rating:
Stock Connect (2014-present): Northbound daily quota expanded; cumulative foreign purchases exceeded RMB 1 trillion by 2020. Foreign investors overwhelmingly buy core assets β their top holdings read like a core asset index.
MSCI inclusion (2018-present): China A-shares included at 20% factor weight. Full inclusion would trigger an estimated $300-400 billion of passive inflows. Each step-up in inclusion factor forces index funds to buy core assets.
FTSE Russell, S&P Dow Jones: Additional index inclusion channels amplify the same dynamic.
Foreign investors bring global valuation standards. They compare Chinese consumer staples to Nestle and Unilever, Chinese pharma to Roche and AstraZeneca. This comparison frequently reveals that Chinese core assets are undervalued relative to global peers despite faster growth, triggering sustained buying.
Zhang draws direct parallels to historical market transitions:
United States (1980s-2000s): The "Nifty Fifty" concept of the 1970s was premature but directionally correct. After the 1982 bottom, U.S. markets were increasingly dominated by a shrinking number of mega-cap quality stocks. By the 2010s, FAANG concentration reached extreme levels. The lesson: once the quality premium takes hold, it persists for decades.
Japan (1970s-1980s): As Japan's GDP growth decelerated from double digits to mid-single digits, the market shifted from cyclical/export stocks to domestic consumer and technology leaders. Toyota, Sony, and consumer franchises dramatically outperformed the broad Nikkei. Zhang notes the parallel is imperfect because Japan's bubble distorted this process.
South Korea (2000s-2010s): After the Asian Financial Crisis, Samsung Electronics, Hyundai, and a handful of chaebol leaders dominated Korean market returns. The KOSPI increasingly became a proxy for Samsung. Foreign ownership of Samsung reached 55%+, driving continuous re-rating.
The common pattern: economic deceleration -> institutional capital influx -> quality concentration -> core asset premium. China is traversing this exact path.
For core assets with stable and predictable cash flows, Zhang advocates a two-stage DCF model:
Stage 1 (Years 1-10): Explicit forecast period
- Revenue growth: Use consensus estimates for Years 1-3, then taper to
long-term sustainable growth by Year 10
- Margins: Hold stable or allow modest expansion if structural drivers exist
- Capex: Normalize to maintenance levels by Year 5-7
- WACC: Use 8-10% for most core assets (lower for utilities, higher for tech)
Stage 2 (Terminal value):
- Terminal growth rate: 3-4% (nominal GDP proxy)
- Terminal FCF margin: Conservative estimate based on mature-state peers
- Gordon Growth Model: TV = FCF_Year10 * (1 + g) / (WACC - g)
Intrinsic Value = Sum(PV of Stage 1 FCFs) + PV(Terminal Value)
Key discipline: the terminal value should not exceed 60-65% of total intrinsic value. If it does, the explicit forecast period assumptions are likely too conservative, or the terminal growth rate is too aggressive. Recalibrate.
For faster-growing core assets where DCF sensitivity is too high, Zhang uses a PEG-adjusted PE framework:
Fair PE = Earnings Growth Rate (%) * PEG ratio
PEG ratio benchmarks by sector:
Consumer Staples: PEG 1.5 - 2.0 (premium for stability)
Healthcare: PEG 1.2 - 1.8 (premium for structural growth)
Technology: PEG 0.8 - 1.5 (discount for disruption risk)
Financials: PEG 0.6 - 1.0 (discount for leverage risk)
Example: A consumer staples core asset growing earnings at 20% per year deserves a PE of 30-40x (20% * 1.5-2.0 PEG). A technology core asset growing at the same rate deserves only 16-30x (20% * 0.8-1.5 PEG).
Zhang articulates the "certainty premium" β investors should pay more for predictable outcomes:
Lower variance of outcomes: Core assets have narrower distributions of future earnings. A stock with 90% probability of 15-25% earnings growth is worth more than one with equal probability of -10% or +50%.
Lower risk of permanent capital loss: Core assets rarely go to zero. Their moats, scale, and financial resources provide a floor on value. This asymmetry justifies higher multiples.
Liquidity premium: Core assets trade with deep liquidity, enabling large institutional positions without market impact. This is independently valuable to institutional investors and supports premium valuations.
Compounding optionality: Core assets can deploy excess cash flow into adjacent opportunities, creating embedded growth options that are difficult to model but genuinely valuable.
Core assets are not immune to overvaluation. Zhang identifies specific warning thresholds:
OVERVALUATION WARNING TRIGGERS:
1. PE exceeds 2x the historical 5-year average PE
2. PE exceeds 3x the forward earnings growth rate (PEG > 3.0)
3. Dividend yield falls below 0.5% for a stock with established payout history
4. Analyst consensus has 0 sell ratings (universal optimism)
5. Retail ownership surges (momentum chasers arriving late)
6. Premium to global peer group exceeds 50% on PE basis
7. Price-to-FCF exceeds 50x for non-hypergrowth company
When 3 or more of these triggers fire simultaneously, the probability of a meaningful correction (20%+ drawdown) within 12 months exceeds 70% historically.
Reference ranges for Chinese core assets (A-share listed):
| Sector | Cheap (Buy Zone) | Fair Value | Expensive (Caution) | Bubble |
|---|---|---|---|---|
| Consumer Staples | PE < 20x | PE 20-35x | PE 35-50x | PE > 50x |
| Healthcare | PE < 25x | PE 25-40x | PE 40-60x | PE > 60x |
| Technology | PE < 20x | PE 20-35x | PE 35-50x | PE > 50x |
| Financials (Banks) | PB < 0.6x | PB 0.6-1.0x | PB 1.0-1.5x | PB > 1.5x |
| Financials (Ins.) | PEV < 0.6x | PEV 0.6-1.0x | PEV 1.0-1.3x | PEV > 1.3x |
These ranges shift over time with interest rates and growth expectations. Use as anchors, not rigid rules.
The primary entry strategy is to buy core assets during temporary valuation compressions while the long-term earnings trajectory remains intact:
ENTRY CONDITION SET A β Valuation Dip Buy:
1. Stock is in the "Cheap" or low end of "Fair Value" zone (Section 4.5)
2. Trailing 12-month price decline >= 20% from peak
3. Forward earnings estimates have NOT been revised down by > 10%
4. The decline is driven by macro/market factors, NOT company-specific deterioration
5. Institutional ownership has remained stable or increased during the decline
If all five conditions are met, initiate a position at 50% of target allocation. Add the remaining 50% if the stock declines a further 10-15% with no fundamental change, or on the first quarterly earnings report that confirms the thesis.
Zhang emphasizes that the best core asset entry points coincide with market-wide panic events β trade wars, pandemic scares, credit crises, regulatory shocks:
ENTRY CONDITION SET B β Panic Buy:
1. Broad market (CSI 300) has declined >= 15% in < 3 months
2. VIX equivalent (China VIX / iVX) is at 12-month highs
3. Margin lending balance has declined >= 20% from peak
4. Northbound (foreign) flows show net selling for 5+ consecutive days
5. Media sentiment is overwhelmingly negative; "bear market" headlines dominate
6. Target core asset PE is in the bottom 20th percentile of its 5-year range
When 4+ of these conditions are met, deploy capital aggressively. These windows are rare (once every 1-3 years) and short (typically 2-6 weeks). The investor must have pre-identified target stocks and valuations BEFORE the panic arrives.
For core assets already held at fair valuations, Zhang identifies earnings acceleration as a signal to increase position size:
ENTRY CONDITION SET C β Earnings Acceleration:
1. Quarterly earnings growth rate exceeds the prior quarter's growth rate
2. Revenue growth is also accelerating (not just margin expansion)
3. Management raises forward guidance or street estimates are revised up >= 5%
4. Operating cash flow confirms earnings quality (OCF/NI > 0.8)
This signal is used to top up existing positions from 50-70% to full 100% target weight, not to initiate new positions from scratch.
Zhang is primarily a fundamental investor but acknowledges the value of technical confirmation for timing:
TECHNICAL CONFIRMATION CHECKLIST:
- Price is above the 200-day moving average (or reclaiming it from below)
- Volume is expanding on up-days relative to down-days
- Relative strength vs. CSI 300 index is stabilizing or turning up
- Stock has broken above a multi-week/month consolidation range
- No bearish divergence on RSI (new price high with lower RSI)
Technical signals serve as tie-breakers when fundamental conditions are borderline. They should never override a negative fundamental assessment.
REDUCE POSITION (sell 30-50%):
- PE reaches the "Expensive" zone AND earnings growth is decelerating
- PEG ratio exceeds 2.5x for consumer/healthcare, 2.0x for tech/financials
- Stock has appreciated > 50% in < 6 months without corresponding earnings growth
FULL EXIT:
- PE reaches the "Bubble" zone (Section 4.5)
- 3+ overvaluation warning signs triggered simultaneously (Section 4.4)
- Company announces large dilutive equity offering at peak valuations
- Fundamental thesis has changed (see Section 6.2)
These are non-negotiable exit triggers regardless of valuation:
IMMEDIATE EXIT TRIGGERS (sell entire position within 5 trading days):
1. MARGIN COMPRESSION: Gross margin declines for 3 consecutive quarters with
no credible recovery plan
2. MARKET SHARE LOSS: Company loses #1 or #2 market share position to a
competitor with a superior product/business model
3. MANAGEMENT CRISIS: CEO/founder departure under contentious circumstances,
accounting fraud allegations, or major governance scandal
4. REGULATORY DESTRUCTION: New regulation that structurally impairs the
business model (not temporary enforcement actions)
5. BALANCE SHEET RISK: Debt-to-equity exceeds 2.0x (non-financial) or
coverage ratios fall below 2x EBITDA/interest
WATCH LIST TRIGGERS (begin reducing position over 1-3 months):
1. Revenue growth decelerates below industry average for 2 quarters
2. Key talent departures across multiple senior positions
3. R&D spending declines as percentage of revenue for 2+ years
4. Customer concentration increases (top client > 30% of revenue)
5. Capex significantly exceeds depreciation for 3+ years without
corresponding revenue growth (empire building)
POSITION SIZING RULES:
Maximum single stock: 8% of total portfolio at cost
12% of total portfolio at market value (let winners run)
Maximum single stock at entry: 5% of total portfolio
Minimum position size: 2% of total portfolio (below this, not worth monitoring)
Number of core asset holdings: 10-20 stocks
Scale position size based on conviction and valuation:
| Conviction | Valuation Zone | Position Size (% of portfolio) |
|---|---|---|
| High | Cheap | 6-8% |
| High | Fair Value | 4-6% |
| High | Expensive | 0-2% (trim or exit) |
| Medium | Cheap | 4-5% |
| Medium | Fair Value | 2-4% |
| Medium | Expensive | 0% (exit) |
SECTOR LIMITS:
Maximum single sector: 35% of total portfolio
Minimum number of sectors: 3 out of 4 primary sectors
If one sector exceeds 35%: Rebalance within 30 trading days
Zhang advocates a 70/30 portfolio structure:
CORE ALLOCATION (70% of total portfolio):
- 10-15 core asset positions
- Held for 3-5 year minimum time horizon
- Rebalanced only on valuation extremes or fundamental changes
- Target: 12-18% annualized return through earnings compounding + modest re-rating
SATELLITE ALLOCATION (30% of total portfolio):
- 5-10 tactical positions
- Emerging core assets (companies growing into core asset status)
- Cyclical quality plays (core assets in cyclical industries during upcycles)
- Event-driven situations (restructuring, spin-offs, regulatory catalysts)
- Shorter holding period: 6-18 months
- Target: 20-30% annualized return with higher risk tolerance
TARGET SECTOR ALLOCATION:
Consumer Staples: 25-35%
Healthcare: 20-25%
Technology: 15-25%
Financials: 10-20%
Other (Industrials/
Materials leaders): 0-10%
Within each sector, hold 2-4 positions to reduce single-stock risk while maintaining concentrated enough positions to be meaningful.
SCHEDULED REBALANCING:
- Review portfolio quarterly after earnings season
- Calculate updated fair values for each holding
- Adjust position sizes if actual weight deviates from target by > 3%
EVENT-DRIVEN REBALANCING:
- Market correction > 15%: Review all positions for opportunistic adding
- Single stock > 12% of portfolio: Trim to 8% over 2-4 weeks
- Sector exceeds 35%: Reduce to 30% within 30 trading days
- Fundamental thesis break: Exit within 5 trading days (Section 6.2)
- New core asset identified: Fund from lowest-conviction existing position
Zhang emphasizes that the minimum effective holding period for core assets is 3-5 years. This is not arbitrary; it is the minimum time required for:
The ideal holding period is "as long as the thesis holds." Zhang cites Moutai holders from 2005-2020 as the definitive example: a 100x return driven almost entirely by earnings compounding, with valuation multiples roughly flat over the full period. The investors who captured this return did nothing except hold.
What to look for:
Key metrics:
Gross margin: > 60% (premium brands), > 40% (mass premium)
Net margin: > 25%
ROE: > 25%
Revenue growth: > 10% sustainably
Advance receipts/
contract liabilities: Growing (demand exceeds supply)
Inventory turnover: Stable or improving
Archetypes: Kweichow Moutai (baijiu), Haitian Flavouring (condiments), Yili Group (dairy), China Tourism Group Duty Free (luxury retail).
Valuation anchor: Consumer core assets can sustain PE 25-35x through full cycles if earnings growth remains 15-20%. Below 20x PE on temporary setbacks is a strong buy signal.
What to look for:
Key metrics:
R&D as % of revenue: > 10% (innovative pharma), > 5% (devices/services)
Revenue from products
launched in last 5 yrs: > 30%
Pipeline value: Use risk-adjusted NPV of late-stage pipeline
Gross margin: > 70% (innovative pharma), > 50% (devices)
Customer diversification: No single hospital/payer > 10% of revenue
Archetypes: Hengrui Medicine (innovative pharma), WuXi AppTec (CRO/CDMO platform), Mindray (medical devices), Aier Eye Hospital (specialty chain).
Valuation anchor: Healthcare core assets command premium PEs of 30-50x due to structural growth in healthcare spending. Use pipeline-adjusted PE: subtract estimated pipeline NPV from market cap, then calculate PE on existing product earnings. Pipeline-adjusted PE should be < 30x.
What to look for:
Key metrics:
Revenue growth: > 20% (growth phase), > 10% (mature platform)
User metrics: DAU/MAU ratio > 50%, user growth positive
Gross margin: > 50% (software/platform), > 25% (hardware)
FCF margin: > 15% (platforms), > 8% (hardware)
R&D as % of revenue: > 10%
Customer retention/
net dollar retention: > 100% (enterprise SaaS)
Archetypes: Tencent, Alibaba (platform), CATL (battery technology leader), Luxshare Precision (hardware supply chain), Will Semiconductor (semiconductors).
Valuation anchor: Technology core assets require more dynamic valuation. Use EV/Revenue for high-growth phases (target 5-10x for 30%+ growers), transition to PE as growth matures. Apply a 20-30% discount to U.S. comparable multiples for regulatory and geopolitical risk.
What to look for:
Key metrics:
Banks:
ROE: > 12%
NPL ratio: < 1.5%, with declining trend
Provision coverage: > 200%
CET1 ratio: > 10%
Fee income as % total: > 25% and growing
Insurance:
Embedded value growth: > 15% annually
New business value
margin: > 30%
Combined ratio (P&C): < 100%
Investment return: > 5% average over cycle
Agent productivity: Improving trend
Archetypes: China Merchants Bank (retail banking), Ping An Insurance (integrated financial platform), China Pacific Insurance (life insurance).
Valuation anchor: Banks are valued on P/B (target 0.8-1.2x for core assets, where book value is credible). Insurance companies are valued on P/EV (price to embedded value), with core assets trading at 0.7-1.2x EV. Both deserve a premium over the sector average but rarely trade above 1.5x P/B or P/EV.
Zhang dedicates significant attention to the psychological challenges of core asset investing:
Core assets almost always look expensive on trailing PE. The investor who waits for Moutai to trade at 15x PE will never own it. Train yourself to evaluate forward earnings power, not trailing multiples. A stock at 35x trailing earnings that is growing at 25% is at 28x forward β reasonable for a core asset.
When small-caps or speculative themes rally 50% in a quarter while your core assets return 5%, the temptation to rotate is intense. Do not. Over a 5-year horizon, core assets overwhelmingly outperform. The small-cap rallies are unpredictable, unrepeatable, and frequently give back gains as fast as they accumulate.
Core asset investing is intentionally boring. You buy quality, hold through volatility, and let compounding work. If you find yourself trading frequently, checking prices hourly, or feeling excited about your portfolio, you are doing it wrong.
Buying dips is correct ONLY when the fundamental thesis is intact. If a core asset is declining because its competitive position is genuinely weakening, averaging down simply increases your exposure to a deteriorating situation. Distinguish between "cheap because of market fear" and "cheap because the business is breaking."
Document every buy and sell decision with:
Quarterly earnings misses, analyst downgrades, macro headlines, and short-term price volatility are noise for a 3-5 year investor. React only to information that changes the structural thesis β competitive position, industry dynamics, management quality, or regulatory framework.
Many investors hold 30-50 small positions because it feels safer. This is diversi-fiction, not diversification. Core asset investing requires concentrated positions (2-8% each in 10-20 stocks) large enough that the compounding matters to your total wealth.
Not every large-cap blue chip is a core asset. State-owned enterprises with low ROE, declining market share, and poor capital allocation are large and liquid but NOT core assets. Apply the screening criteria rigorously; name recognition is not a substitute for fundamental quality.
The worst time to discover core asset investing is at the end of a multi-year bull run when every commentator is praising quality stocks. Buying Moutai at 70x PE or a consumer stock at PEG > 3.0 is speculation disguised as value investing. Entry valuation still matters enormously for forward returns.
Investors who buy core assets but trade them on 10-20% swings destroy the compounding advantage. Transaction costs, capital gains taxes, and the near-impossibility of consistently timing re-entry mean that frequent trading with core assets underperforms buy-and-hold by 3-5% annually.
Chinese core assets do not exist in isolation. When U.S. treasuries sell off sharply, global risk appetite contracts, and foreign investors sell A-shares. When the Fed tightens aggressively, Chinese core asset valuations face headwinds regardless of local fundamentals. Monitor global macro conditions as they affect the demand side of the valuation equation.
Owning 8 consumer staples stocks is not diversification. If the consumer sector de-rates due to a demand shock, economic downturn, or regulatory action (e.g., anti-monopoly enforcement), all 8 positions will decline together. Diversify across sectors, not just across companies within a single sector.
Your cost basis is irrelevant to forward decision-making. If a core asset has appreciated 100% and is now in the "Bubble" valuation zone, the correct action is to trim regardless of whether you have a gain or loss. Similarly, if a stock is 30% below your purchase price but still in the "Fair Value" zone, there is no reason to sell simply because it shows a loss.
The 30% satellite allocation exists for a reason: it provides tactical flexibility, captures emerging opportunities, and satisfies the natural human desire for action. Investors who allocate 100% to core assets often break discipline during speculative market phases because they have no outlet for tactical instincts.
A company, "Leader Pharma" (fictional), appears on the core asset screener:
Screening results:
ROE (3-year average): 22% PASS (>= 15%)
Gross margin (3-year avg): 78% PASS (>= 30%)
Revenue CAGR (5-year): 24% PASS (>= 10%)
FCF positive: 5/5 yrs PASS
Market share: #1 CRO PASS
Debt-to-equity: 0.3x PASS (< 1.0x)
Dividend history: 3 years PASS
Secondary score: +8 PASS (>= 5)
(+3 ROE > 20%, +2 CAGR > 15%, +2 margin expanding, +1 foreign buying)
Conduct fundamental analysis:
Valuation assessment:
Current price: CNY 120
Trailing PE: 55x
Forward PE (consensus): 42x
Earnings growth (next 2yr): 30% CAGR
PEG ratio: 1.4x (42/30)
Sector PEG benchmark: 1.2-1.8x
Valuation zone: Fair Value (middle of range)
Decision: The stock passes all fundamental criteria but is not yet cheap enough for a full position. Add to the watchlist with a target entry PE of 35x or below (which implies a ~17% pullback from current levels).
A broad market correction driven by rising U.S. treasury yields causes CSI 300 to decline 12% over 6 weeks. Leader Pharma falls to CNY 100 (PE drops to 38x forward). Earnings estimates are unchanged.
Entry Condition Set A check:
1. Valuation: 38x forward PE, low end of Fair Value PASS
2. Price decline: -17% from peak PARTIAL (close to 20%)
3. Earnings revisions: No downward revision PASS
4. Decline driver: Macro, not company-specific PASS
5. Institutional ownership: Stable PASS
Decision: Initiate at 50% target weight (3% of portfolio at CNY 100).
Leader Pharma continues declining to CNY 90 (PE 34x forward) as the correction deepens. Fundamentals remain intact. Add remaining 50% (additional 3% of portfolio). Total position: 6% of portfolio at average cost of CNY 95.
Over the next 3 years, Leader Pharma's earnings grow at 28% CAGR (slightly below the 30% estimate but within acceptable range). The stock appreciates from CNY 95 average cost to CNY 220.
Quarterly review process each earnings season:
At Month 24, the stock briefly exceeds CNY 250 (PE reaches 50x forward). This enters the "Expensive" zone. Trim 30% of the position (sell 1.8% of portfolio), reducing holding to 4.2% of portfolio at market.
At Month 40, a new geopolitical development restricts cross-border pharmaceutical data sharing. Leader Pharma's top 5 global clients (40% of revenue) indicate they will reduce outsourcing to China. Analyst estimates are cut by 15%.
Fundamental deterioration check:
Regulatory destruction of business model? PARTIAL β significant impairment
Revenue concentration risk materialized? YES β top 5 clients reducing orders
Management response credible? UNCLEAR β pivoting to domestic but
domestic market is smaller and lower-margin
Decision: This constitutes a structural thesis change, not a temporary setback. Exit the remaining position over 2 weeks. Sell at average CNY 195.
Initial investment: 6.0% of portfolio at CNY 95
Partial trim: 1.8% of portfolio sold at CNY 250 (+163%)
Final exit: 4.2% of portfolio sold at CNY 195 (+105%)
Blended return: +120% over 40 months = ~30% annualized
Holding period: 3.3 years (within the 3-5 year target range)
The investment succeeded because of disciplined entry (buying during a correction), patient holding through volatility, partial profit-taking at expensive valuations, and decisive exit when the structural thesis changed.
"Core assets are not a style or a theme β they are the inevitable destination of a maturing capital market. Every developed market in history has gone through this transition. China is not an exception; it is simply later to the process."
"The biggest risk in investing is not volatility β it is owning mediocre businesses at any price. A 50% drawdown in a core asset is a buying opportunity. A 50% drawdown in a weak company may be permanent destruction."
"When foreign capital looks at China, they see 10-15 world-class businesses trading at a discount to inferior global peers. The valuation gap will close. The only question is when, not whether."
"Do not confuse patience with passivity. Holding core assets requires more conviction, more research, and more discipline than trading. The holder must continuously re-underwrite the thesis while resisting the urge to act on noise."
"In a market of 4,000 listed companies, perhaps 100-200 qualify as core assets at any given time. Of those, perhaps 30-50 are attractively valued. Your job as an investor is to own 10-20 of the best and ignore everything else."
"The certainty premium is real and justified. Paying 30x earnings for a business that will almost certainly grow 20% for the next 5 years is mathematically superior to paying 10x for a business that may grow 30% or may decline 20%. Expected value is not the same as expected experience."
"The transition from a retail-dominated market to an institutional market is a one-way door. Once foreign capital, mutual funds, and pension assets reach critical mass, the premium for quality and liquidity becomes self-reinforcing. Volatility decreases, correlations within the core asset basket increase, and the gap between core and non-core widens permanently."
"Every bear market is a gift to the core asset investor. The stocks go on sale, but the businesses continue to compound. If you have done your fundamental work, market panic is not a time for fear β it is the time when future returns are being maximized."
End of Implementation Specification